AlanSandlerMD

Professor of Medicine, Oregon Health & Sci University

Dr. Sandler is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1989 - 1992
Yale-New Haven Medical CenterResidency, Internal Medicine, 1987 - 1989
Rush Medical College of Rush University Medical CenterClass of 1987

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2012

PubMed

7 citations
C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients.
Namrata Patil, Wei Zou, Simonetta Mocci, Alan Sandler, Marcus Ballinger
Plos One. 2021-02-03
865 citations
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Roy S. Herbst, Giuseppe Giaccone, Filippo de Marinis, Niels Reinmuth, Alain Vergnenegre
The New England Journal of Medicine. 2020-09-30
326 citations
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
Robert M. Jotte, Federico Cappuzzo, Ihor Vynnychenko, Daniil Stroyakovskiy, Delvys Rodriguez-Abreu
Journal of Thoracic Oncology. 2020-08-01

Journal Articles

Differential Regulation of PD-L1 Expression by Immune and Tumor Cells in NSCLC and the Response to Treatment with Atezolizumab (Anti–PD-L1)
Alan Sandler, David S Shames, Hartmut Koeppen, Jamie Chaft, Scott N Gettinger, Alexander Spira, Daniel S Chen, Naiyer A Rizvi, David R Spigel, Proceedings of the National Academy of Sciences